Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer

Join us for this dynamic, live stream, CME-certified webinar where experts will provide their insights on the optimal use of immune checkpoint inhibitors in the treatment of NSCLC via a series of patient cases, including discussion of the latest clinical data in early-stage and advanced-stage disease, clinical factors influencing response to these agents, and how emerging data may affect current treatment paradigms. This event will offer attendees the opportunity to have their questions answered by the expert faculty.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the webinar.

Agenda

  • Welcome and Introduction
  • Overview of Immunotherapy in Early-Stage NSCLC
  • Evolving Role of Immunotherapy in Newly Diagnosed Advanced or Metastatic NSCLC
  • Practical Considerations: Clinical Factors Influencing Response to Immune Checkpoint Inhibition
  • What to Do After Progression on Immune Checkpoint Inhibitor Therapy: Future Directions
  • Final Panel Discussion and Audience Question and Answer Session

Faculty

Program Director
Julie R. Brahmer, MD

Professor of Oncology
Director, 
Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Faculty
Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital
RCSI University of Medicine and Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in immuno-oncology for the treatment of non-small-cell lung cancer.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal first-line immune checkpoint inhibitor and chemotherapy combinations for patients with advanced or metastatic NSCLC
  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC
  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy and in those who are ineligible for surgery or chemoradiation therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
  • Address factors that have the potential to reduce efficacy of ICI therapy in individual patients with NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.